Pivotal readout
Novartis pelacarsen cuts Lp(a) by 78% but fails to reduce heart events
Full Lp(a)HORIZON results in 8,323 patients showed TQJ230 sharply lowered lipoprotein(a) yet left the composite of cardiovascular events unchanged versus placebo. Injection-site and flu-like reactions were more common, and 19 anaphylaxis cases occurred on the drug. Novartis had disclosed the topline miss in September and wrote down the asset.
Written by Gosset from public sources. Source types: News article. Sources are available to Gosset users. Log in to see them.